Trump Administration Advances Federal Marijuana Rescheduling; Tilray Stock in Focus
President Donald Trump has directed federal officials to expedite efforts to reclassify marijuana from Schedule I to Schedule III, a move that survived recent legal challenges. A federal appeals court rejected an attempt by anti-marijuana groups to halt the process while litigation continues. While this does not guarantee rescheduling success, it keeps the initiative viable and could significantly impact medical cannabis research and access. Tilray Brands (TLRY) is highlighted as a potential beneficiary of such policy changes due to its strong presence in international medical cannabis markets. The company reported $915 million in revenue for fiscal 2026 with improved financials, including positive operating cash flow and reduced debt. Tilray's expansion into alcohol brands, wellness products, and hospitality through the acquisition of BrewDog diversifies its business beyond cannabis. Despite progress, federal rescheduling remains uncertain due to ongoing legal challenges and administrative delays. The appeals court’s recent decision only prevents a temporary block but does not resolve broader litigation.
Tickers: $TLRY